GEN-MKT-18-7897-A
Jun 27, 2019 | Blogs, Clinical | 0 comments
Aaron Hudson is Vice President and General Manager, Clinical Diagnostics at SCIEX. Aaron has been with SCIEX for over 17 years, beginning as a Sales Representative, and holding various roles including Director Global Marketing Strategy & Brand. Aaron holds a Ph.D. in Molecular Genetics and Protein Chemistry from University of Sheffield, UK.
SCIEX pioneers innovative solutions in mass spectrometry to enable the accurate quantification of molecules in complex samples. The clinical diagnostic portfolio includes an FDA-cleared assay for in vitro diagnostic use, medical device mass spectrometers and fully integrated LC-MS/MS systems with easy to learn, intuitive software. As part of the Danaher family of global life science and technology innovators, SCIEX has led the field of mass spectrometry for nearly 50 years.
Question: What are the top 3 reasons labs should be considering LC-MS/MS (mass spec) for in-house testing?
Answer: In my mind, the first reason is the “3 S’s”; sensitivity, specificity, and selectivity to deliver more accurate quantification, and ultimately better patient care. LC-MS/MS can overcome problems associated with interference, cross-reactivity, and lot-to-lot variability that can be observed with immunoassays. The second is multiplexing. You can combine dozens of analytes into a single, fast, assay. Definitive drugs of abuse testing is a good example of this and typically you can analyze over 80 drugs in under five mins, but you can also multiplex proteins, lipids, and metabolites. Third would be simpler development of LDT’s to bring more testing in-house to achieve cost reduction and decreased turnaround times – critical elements in today’s clinical environment. This also enables the translation of novel biomarkers into clinical utility.
Answer: In my mind, the first reason is the “3 S’s”; sensitivity, specificity, and selectivity to deliver more accurate quantification, and ultimately better patient care. LC-MS/MS can overcome problems associated with interference, cross-reactivity, and lot-to-lot variability that can be observed with immunoassays.
The second is multiplexing. You can combine dozens of analytes into a single, fast, assay. Definitive drugs of abuse testing is a good example of this and typically you can analyze over 80 drugs in under five mins, but you can also multiplex proteins, lipids, and metabolites.
Third would be simpler development of LDT’s to bring more testing in-house to achieve cost reduction and decreased turnaround times – critical elements in today’s clinical environment. This also enables the translation of novel biomarkers into clinical utility.
Question: How has mass spec evolved in the clinical arena?
Answer: My earliest memories of mass spec in clinical date back 20 years to my sales rep days when ‘tandem mass spec’ was emerging for neonatal screening. Since then more and more assays have been adapted based on the figures of merits I outlined earlier and so now I don’t think there is any doubt that mass spec is seen as the gold standard for many assays. The next era will see mass spec simplified to be a more integrated part of the core clinical chemistry lab.
Question: LC-MS/MS in the clinical lab isn’t just about the technology anymore. What other benefits are vital to the end-user experience?
Answer: At SCIEX we believe that customer experience is just as important as the instrument hardware. From installation, method setup, to results production and information management, a robust standard work process is needed. SCIEX has numerous resources needed to provide an end-to-end solution: The SCIEX clinical applications team is full of experts familiar with clinical applications; SCIEX Now provides responsive support, and online resources like SCIEX University is a great platform for further education for our end-users for all things Mass Spec. SCIEX is your partner.
Learn More About SCIEX Systems for Your Clinical Lab >
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.
In a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.
Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
Posted by
You must be logged in to post a comment.
Share this post with your network